Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19477970 | 0.87 | MLYCD (0.32) | ALDH1A1PKMMLYCD | |
| SCHEMBL12783366 | 0.85 | ALDH1A1 (0.50) | ALDH1A1PKMMLYCDOPRM1OPRD1 | |
| SCHEMBL23872654 | 0.82 | ALOX5 (0.35) | ALDH1A1PKMMLYCDALOX5OPRM1 | |
| SCHEMBL21789735 | 0.79 | MLYCD (0.38) | ALDH1A1PKMMLYCDALOX5OPRM1 | |
| SCHEMBL678573 | 0.78 | LMNA (0.42) | ALDH1A1PKMMLYCDOPRM1SLC6A2 | |
| SCHEMBL17472047 | 0.77 | ALDH1A1 (0.41) | ALDH1A1PKMMLYCDALOX5 | |
| SCHEMBL24890720 | 0.76 | CNR2 (0.36) | ALDH1A1PKMMLYCDALOX5 | |
| SCHEMBL25564696 | 0.75 | ALOX5 (0.39) | ALDH1A1PKMMLYCDALOX5 | |
| SCHEMBL3483327 | 0.74 | ALOX5 (0.41) | ALOX5OPRM1OPRD1 | |
| SCHEMBL23872422 | 0.73 | ALOX5 (0.38) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022236319-A1 | NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |